KDR and ovarian carcinoma: These results collectively demonstrate that PS VII can also exhibit a synergistic therapeutic effect with PARPi in vivo through the RORα/ECM1/VEGFR2 signaling pathway and plays a critical role in suppressing the growth and metastasis of PARP inhibitor-resistant ovarian cancer tumors.